Boehringer Ingelheim: Clinical Trials & FDA Approval Profile
Boehringer Ingelheim (Ingelheim, DE / Ridgefield, CT) sponsors 139 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 45 active protocols (28 recruiting now), 70 completed protocols, and 54 all-time original FDA Drugs@FDA NDA and BLA approvals.